Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: respiratory disorder therapeutics - Pulmatrix

Next Previous
Drug Profile

Research programme: respiratory disorder therapeutics - Pulmatrix

Alternative Names: Fluticasone/salmeterol dry powder - Pulmatrix; Levofloxacin dry powder - Pulmatrix; PUR 0400; PUR 0500; PUR 0600; PUR 0700; PUR 1000; PUR 113; PUR 1500; PUR 1700; Salmeterol/fluticasone dry powder - Pulmatrix; SD 101 - Pulmatrix; SD 102

Latest Information Update: 22 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pulmatrix
  • Class Androstadienes; Anti-inflammatories; Biological proteins; Fluoroquinolones; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists; Immunomodulators; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis-associated respiratory tract infections; Idiopathic pulmonary fibrosis; Influenza virus infections; Respiratory tract disorders; Respiratory tract infections

Most Recent Events

  • 22 Feb 2023 Discontinued - Preclinical for Asthma in USA (Inhalation)
  • 22 Feb 2023 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (Inhalation)
  • 22 Feb 2023 Discontinued - Preclinical for Cystic fibrosis-associated respiratory tract infections (Prevention) in USA (Inhalation)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top